sulfasalazine has been researched along with Bone Cancer in 4 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulfasalazine (SAS) is an FDA-approved drug for the treatment of Crohn's disease, rheumatoid arthritis, and inflammatory bowel disease." | 5.72 | Iron plays a role in sulfasalazine-induced ferroptosis with autophagic flux blockage in K7M2 osteosarcoma cells. ( Liu, J; Lou, C; Lv, H; Shang, P; Wang, Y; Zhen, C, 2022) |
| "Sulfasalazine (SAS) is an FDA-approved drug for the treatment of Crohn's disease, rheumatoid arthritis, and inflammatory bowel disease." | 1.72 | Iron plays a role in sulfasalazine-induced ferroptosis with autophagic flux blockage in K7M2 osteosarcoma cells. ( Liu, J; Lou, C; Lv, H; Shang, P; Wang, Y; Zhen, C, 2022) |
| "In sum, we demonstrate how breast cancer bone metastases upregulate a cystine/glutamate co-transporter to elevate extracellular glutamate." | 1.43 | The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain. ( BassiriRad, NM; Bui, L; Doyle, T; Forte, BL; Largent-Milnes, TM; Mantyh, PW; Neumann, WL; Salvemini, D; Slosky, LM; Staatz, WD; Symons, AM; Thompson, M; Vanderah, TW, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, J | 1 |
| Lou, C | 1 |
| Zhen, C | 1 |
| Wang, Y | 1 |
| Shang, P | 1 |
| Lv, H | 1 |
| Eyre, R | 1 |
| Alférez, DG | 1 |
| Santiago-Gómez, A | 1 |
| Spence, K | 1 |
| McConnell, JC | 1 |
| Hart, C | 1 |
| Simões, BM | 1 |
| Lefley, D | 1 |
| Tulotta, C | 1 |
| Storer, J | 1 |
| Gurney, A | 1 |
| Clarke, N | 1 |
| Brown, M | 1 |
| Howell, SJ | 1 |
| Sims, AH | 1 |
| Farnie, G | 1 |
| Ottewell, PD | 1 |
| Clarke, RB | 1 |
| Slosky, LM | 1 |
| BassiriRad, NM | 1 |
| Symons, AM | 1 |
| Thompson, M | 1 |
| Doyle, T | 1 |
| Forte, BL | 1 |
| Staatz, WD | 1 |
| Bui, L | 1 |
| Neumann, WL | 1 |
| Mantyh, PW | 1 |
| Salvemini, D | 1 |
| Largent-Milnes, TM | 1 |
| Vanderah, TW | 1 |
| Preston, SJ | 1 |
| Clifton-Bligh, P | 1 |
| Laurent, MR | 1 |
| Jackson, C | 1 |
| Mason, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Methadone for 'Adenocarcinopathic' Pain Treatment: Methadone vs. Morphine Vanguard RCT[NCT05325164] | Phase 3 | 0 participants (Actual) | Interventional | 2022-09-30 | Withdrawn (stopped due to Trial not started; change in Sponsor and Principal Investigator, trial to be registered again by new Sponsor/Investigator if it is started.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for sulfasalazine and Bone Cancer
| Article | Year |
|---|---|
Iron plays a role in sulfasalazine-induced ferroptosis with autophagic flux blockage in K7M2 osteosarcoma cells.
Topics: Antioxidants; Bone Neoplasms; Cell Line, Tumor; Child; Ferroptosis; Humans; Iron; Osteosarcoma; Reac | 2022 |
Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cell Line | 2019 |
The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiporters; Bone Neoplasms; Breas | 2016 |
Effect of methotrexate and sulphasalazine on UMR 106 rat osteosarcoma cells.
Topics: Alkaline Phosphatase; Animals; Antirheumatic Agents; Bone Neoplasms; Cell Count; Cell Division; Cell | 1997 |